Search research articles
Contact Us
Filters
Showing results (1-10 of 100) with videos related to
Page
of 10
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 19, 2017
Biomarker-Based Treatment Selection in Non-Small Cell Lung Cancer
Wallace Akerley
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 9, 2017
Retrospective, Multi-Institutional Analysis of Sequential Treatment of Brain Metastases in Treatment-Naïve, Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer Should Not Define the Standard of Practice
Anna Chalmers, Wallace Akerley
The Oncologist
|
January 2, 2019
Adverse Event Management in Patients with <i>BRAF</i> V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib
Anna Chalmers, Laura Cannon, Wallace Akerley
Lung Cancer (Amsterdam, Netherlands)
|
November 28, 2017
Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report
Anna Chalmers, Leif Jensen, Wallace Akerley
Lung Cancer (Amsterdam, Netherlands)
|
October 1, 2013
A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis
Richard E Nelson, David Stenehjem, Wallace Akerley
Anti-Cancer Agents in Medicinal Chemistry
|
September 28, 2007
Oncologists' current opinion on the treatment of colon carcinoma
Martin Majer, Wallace Akerley, Scott K Kuwada
Clinical Lung Cancer
|
March 19, 2023
Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib
Jarrod T Smith, Sonam Puri, Wallace Akerley
American Journal of Clinical Oncology
|
March 26, 2015
Squamous non-small cell lung cancer as a distinct clinical entity
Trudy G Oliver, Jesal Patel, Wallace Akerley
Journal of Thoracic Disease
|
May 1, 2018
Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care?
Anna W Chalmers, Shiven B Patel, Wallace Akerley
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 3, 2026
TTF-1-Negative Lung Adenocarcinoma: An Aggressive Subtype Refractory to Immunotherapy and KRAS<sup>G12C</sup> Inhibition
Henry U Arnold, Wallace Akerley, Eric L Snyder
Page
of 10
Search research articles
Search
Showing results (1-10 of 100) with videos related to
Sort By:
Page
of 10
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 19, 2017
Biomarker-Based Treatment Selection in Non-Small Cell Lung Cancer
Wallace Akerley
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 9, 2017
Retrospective, Multi-Institutional Analysis of Sequential Treatment of Brain Metastases in Treatment-Naïve, Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer Should Not Define the Standard of Practice
Anna Chalmers, Wallace Akerley
The Oncologist
|
January 2, 2019
Adverse Event Management in Patients with <i>BRAF</i> V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib
Anna Chalmers, Laura Cannon, Wallace Akerley
Lung Cancer (Amsterdam, Netherlands)
|
November 28, 2017
Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report
Anna Chalmers, Leif Jensen, Wallace Akerley
Lung Cancer (Amsterdam, Netherlands)
|
October 1, 2013
A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis
Richard E Nelson, David Stenehjem, Wallace Akerley
Anti-Cancer Agents in Medicinal Chemistry
|
September 28, 2007
Oncologists' current opinion on the treatment of colon carcinoma
Martin Majer, Wallace Akerley, Scott K Kuwada
Clinical Lung Cancer
|
March 19, 2023
Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib
Jarrod T Smith, Sonam Puri, Wallace Akerley
American Journal of Clinical Oncology
|
March 26, 2015
Squamous non-small cell lung cancer as a distinct clinical entity
Trudy G Oliver, Jesal Patel, Wallace Akerley
Journal of Thoracic Disease
|
May 1, 2018
Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care?
Anna W Chalmers, Shiven B Patel, Wallace Akerley
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 3, 2026
TTF-1-Negative Lung Adenocarcinoma: An Aggressive Subtype Refractory to Immunotherapy and KRAS<sup>G12C</sup> Inhibition
Henry U Arnold, Wallace Akerley, Eric L Snyder
Page
of 10